Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Neville D YeomansDavid Yates GrahamM E HusniD H SolomonT StevensJ VargoQ WangL M WisniewskiK E WolskiJ S BorerP LibbyA M LincoffT F LüscherW BaoC WalkerS E Nissennull nullPublished in: Alimentary pharmacology & therapeutics (2018)
Arthritis patients taking NSAIDs plus esomeprazole have infrequent clinically significant gastrointestinal events. Co-prescribed with esomeprazole, celecoxib has better overall GI safety than ibuprofen or naproxen at these doses, despite treatment with low-dose aspirin or corticosteroids.
Keyphrases
- clinical trial
- low dose
- study protocol
- end stage renal disease
- rheumatoid arthritis
- phase ii
- open label
- chronic kidney disease
- newly diagnosed
- ejection fraction
- double blind
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- coronary artery disease
- cardiovascular events
- postoperative pain
- antiplatelet therapy
- combination therapy
- percutaneous coronary intervention
- anti inflammatory drugs
- smoking cessation